68Ga-PSMA PET/CT在生化复发前列腺癌中的表现及其与基因组数据的关联
该回顾性研究纳入603例生化复发或PSA持续升高且无已知转移的前列腺癌患者,评估68Ga-PSMA PET/CT的复发检出率及其与基因组改变的关系。总体检出率为59.2%,阳性预测值为0.98;TP53突变与更短的PET确认生化复发时间及边缘性更高的SUVmax相关。
要点
- 68Ga-PSMA PET/CT总体复发检出率59.2%,阳性预测值0.98。
- PSA<0.5 ng/mL患者中43.8%PET阳性,提示低PSA亦可检出复发。
- TP53突变者PET确认生化复发中位时间4.3年,野生型5.3年(P=0.04)。
核心结论
- 68Ga-PSMA PET/CT可检出前列腺癌复发,甚至在高PSA水平较低的患者中亦然。
- 基因组分析中TP53改变与更短的PET确认生化复发时间相关,并与更高SUVmax呈边缘性相关,提示整合诊断可能识别更具侵袭性的疾病。
研究设计与样本
- 回顾性纳入603例生化复发或PSA持续升高且无已知转移的前列腺癌患者,平均PSA 1.0 ng/mL(范围0.08-5)。
- 所有扫描由两名经验丰富的核医学医师独立分析复发情况,分歧由额外专家读者解决。
- 239例患者子集接受了MSK-IMPACT测序检测进行肿瘤基因组分析。
主要发现
- 68Ga-PSMA PET/CT总体复发检出率为59.2%(357/603),阳性预测值为0.98(95%CI 0.94-0.99),灵敏度为0.60(95%CI 0.54-0.66)。
- 按PSA水平分析,PSA<0.5 ng/mL患者中43.8%PET阳性,PSA 0.5-0.99 ng/mL为64.1%,PSA 1.0-1.99 ng/mL为73.6%,PSA>2.0 ng/mL为87%。
- 读者间一致性极好,κ系数为0.884。
- PSA较高患者(P<0.001)和盆腔外淋巴结转移患者(P<0.001)的SUVmax显著更高。
- PSA持续升高、较高TNM分期、较高Gleason评分及基线未接受放疗的患者(均P<0.001)至PET确认生化复发时间更短。
临床怎么用
- 对于生化复发或PSA持续升高且无已知转移的前列腺癌患者,可考虑行68Ga-PSMA PET/CT以检测复发。
- TP53突变状态可能有助于识别复发更快、SUVmax更高的侵袭性亚群,提示整合基因组与影像诊断的潜在价值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE: To assess the performance of 68Ga-PSMA PET/CT in detecting biochemically recurrent prostate cancer and evaluate associations of PET imaging findings with alterations on genomic profiling. METHODS: 68Ga-PSMA PET/CT scans of 603 prostate cancer patients with biochemical recurrence or persistently elevated PSA and without known metastatic disease were retrospectively included (mean PSA 1.0 ng/mL; range, 0.08-5). All scans were analysed for presence of recurrence by two experienced nuclear medicine physicians independently; discrepancies were resolved by an additional expert reader. A subset of patients (n = 239) had undergone tumour genetic profiling using the Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) sequencing assay. PET positivity and positive predictive value, inter-reader agreement, as well as associations between patient characteristics, location of recurrence, time to PET confirmed biochemical recurrence (PCBR), SUVmax, and most frequent gene alterations were investigated. RESULTS: The overall recurrence detection rate of 68Ga-PSMA PET/CT was 59.2% (357/603), with a positive predictive value of 0.98 (95% CI, 0.94-0.99), and a sensitivity of 0.60 (95% CI, 0.54-0.66). When analysed by PSA level, 43.8% of patients with PSA < 0.5 ng/mL, 64.1% with PSA 0.5-0.99 ng/mL, 73.6% with PSA 1.0-1.99 ng/mL, and 87% with PSA > 2.0 ng/mL were PET positive. Inter-reader agreement was excellent with κ-coefficient of 0.884. SUVmax was significantly higher in patients with higher PSA (P < 0.001), and extra-pelvic nodal metastases (P < 0.001). Patients with persistently elevated PSA, higher TNM stage, higher Gleason score, and without RT at baseline (all P < 0.001) had shorter time to PCBR. In patients with genetic alteration available, TP53 mutations were significantly associated with time to PCBR (alteration, n = 38; wildtype, n = 200; median time 4.3 versus 5.3 years, P = 0.04), and borderline significantly associated with SUVmax (median 11 versus 7, n = 33 and 121, P = 0.054). CONCLUSION: 68Ga-PSMA PET/CT can detect prostate cancer recurrence potentially even among patients with a low PSA level. TP53 alterations on genetic analysis were associated with shorter time to PCBR and borderline associated with higher SUVmax, suggesting that an integrated diagnostic approach may identify more aggressive disease.
引用
- Leithner D, Michaud L, Zheng J, et al. 68Ga-PSMA PET/CT in biochemically recurrent prostate cancer: association with genomic data. Eur J Nucl Med Mol Imaging. 2026. PMID: 42435202. doi:10.1007/s00259-026-08049-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。